No Data
Cathay Biotech Inc. (688065.SH): plans to jointly invest with entities like Creative Technology to establish a partnership.
On December 16, Longtenghui reported that Cathay Biotech Inc. (688065.SH) announced that in May 2024, it will sign a tripartite strategic cooperation agreement with the Hefei Municipal Government and China Merchants Innovation Technology Group Co., Ltd. (referred to as "China Merchants Innovation Technology"). The parties will fully leverage their respective advantages in industrial policy guidance, application scenario creation, and biomanufacturing technology innovation to build a synthetic biological materials industry cluster. According to the cooperation arrangement in the strategic agreement, to better promote the industrialization of a series of bio-based polyamide composite materials, the three parties will collaborate to establish related entities to engage in the research and development, production of bio-based polyamide composite materials and.
Cathay Biotech Inc. (688065.SH): The company's controlling Shareholder will change from CIB to Shanghai Yao Xiu.
On December 16, Gelonghui reported that Cathay Biotech Inc. (688065.SH) announced that, according to the "Stock Contribution Agreement" signed by its controlling shareholder Cathay Industrial Biotech Ltd. (referred to as "CIB") on June 25, 2023, as part of the overall plan for the issuance of A-shares to specific targets in 2023, CIB intends to transfer its directly held 116,655,640 shares of RMB ordinary A-shares to the Shanghai Yaoqin Biotechnology Partnership (Limited Partnership) (to be established) (subject to final business approval and registration).
Cathay Biotech Inc. (688065.SH): The private placement application has obtained the approval and registration reply from the China Securities Regulatory Commission.
On December 3, Gelonghui reports that Cathay Biotech Inc. (688065.SH) announced that the company recently received the document from the China Securities Regulatory Commission entitled "Approval of the Issuance of Stocks by Shanghai Cathay Biotech Inc. to Specific Investors" (Zheng Jian Xu Ke [2024] No. 1662), with the content of the approval document as follows: 1. The application for the registration of the issuance of stocks to specific investors is approved. 2. This issuance must be strictly implemented according to the submitted declaration documents and issuance plan to the Shanghai Stock Exchange. 3. This approval is valid for 12 months from the date of registration approval.
Cathay Biotech Inc. (688065.SH): The developed bio-based polyimide continuous fiber composite materials have begun sample trial production and verification in the fields of new energy, modern architecture, transportation logistics, etc.
On November 21, Gelonghui reported that cathay biotech inc. (688065.SH) stated on the investor interaction platform that currently, the bio-based polyamide continuous fiber composite materials developed by the company have begun sample production and validation in the fields of new energy fund, modern construction, and logistics. Based on the cost-performance advantages and market potential of these bio-based new materials, the company has conducted business connections with multiple subsidiaries and joint ventures of China Merchants Group, and several pilot projects are underway.
Cathay Biotech: third quarter report 2024
Third Quarter Report 2024
Investors Could Be Concerned With Cathay Biotech's (SHSE:688065) Returns On Capital
